Psychopharmacology and Psychiatry Updates
by Psychopharmacology Institute
Is this your podcast?On the show
From 10 epsHosts
Recent guests
Recent episodes
Are Z-Drugs Safe in the First Trimester of Pregnancy?
Oct 18, 2026
17m 58s
Glutamatergic Augmentation in OCD
Oct 13, 2026
16m 21s
Schizophrenia: Which of Seven Antipsychotics Wins?
Oct 9, 2026
15m 15s
SSRI Dosing for OCD: Beyond FDA Guidelines
Oct 3, 2026
9m 10s
Trazodone for Insomnia and Comorbid Depression
Sep 28, 2026
10m 57s
Insights from recent episode analysis
Audience Interest
Podcast Focus
Publishing Consistency
Platform Reach
Insights are generated by CastFox AI using publicly available data, episode content, and proprietary models.
Most discussed topics
Brands & references
Total monthly reach
Based on 1 signal.
Built from
By chart position
- 🇺🇸United States · MedicineHOME#8423K to 121K
- 🇸🇦SA · Medicine#133.0K to 16K
- 🇨🇦Canada · Medicine#831.1K to 5.6K
- 🇮🇳India · Medicine#97875 to 4.6K
- 🇨🇿CZ · Medicine#30495 to 2.6K
- Per-Episode Audience
Est. listeners per new episode within ~30 days
32K to 169K🎙 ~2x weekly·100 episodes·Last published yesterday - Monthly Reach
Unique listeners across all episodes (30 days)
64K to 338K🇺🇸72%🇸🇦9%🇨🇦3%+11 more - Active Followers
Loyal subscribers who consistently listen
35K to 186K
Market Insights
Platform Distribution
Reach across major podcast platforms, updated hourly
Total Followers
—
Total Plays
—
Total Reviews
—
* Data sourced directly from platform APIs and aggregated hourly across all major podcast directories.
Social Links & Contact
Official channels & resources
Official Website
Login
RSS Feed
Login
| Date | Episode | Topics | Guests | Brands | Places | Keywords | Sponsor | Length | |
|---|---|---|---|---|---|---|---|---|---|
| 10/18/26 | Are Z-Drugs Safe in the First Trimester of Pregnancy? | In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't increased, what the neural tube defect signal means, and how to evaluate insomnia before prescribing. Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 86 Are Z-Drugs Safe in the First Trimester of Pregnancy? | 17m 58s | ||||||
| 10/13/26 | Glutamatergic Augmentation in OCD | Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation Glutamatergic Augmentation in OCD: Memantine, Riluzole, Lamotrigine and Other Agents | 16m 21s | ||||||
| 10/9/26 | Schizophrenia: Which of Seven Antipsychotics Wins? | Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 0.75 CMEs: Quick Take Vol. 85 Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety? | 15m 15s | ||||||
| 10/3/26 | SSRI Dosing for OCD: Beyond FDA Guidelines | Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines Treatment-Resistant OCD: From SSRIs to Augmentation | 9m 10s | ||||||
| 9/28/26 | Trazodone for Insomnia and Comorbid Depression | In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia and depression, alongside its notable side effect profile. Can a decades-old antidepressant be the missing link for restorative sleep? Faculty: Paul Zarkowski, M.D. Host: Flavio Guzmán, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 85 Trazodone for Insomnia and Comorbid Depression: Are the AASM Guidelines Relevant? | 10m 57s | ||||||
| 9/23/26 | Antipsychotics, Prolactin, and Sexual Side Effects | In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know Managing Hyperprolactinemia and Sexual Side Effects from Antipsychotic Use | 8m 48s | ||||||
| 9/18/26 | EMERGENT-5: Cobenfy and Treatment Durability | In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.5 CME: Quick Take Vol. 85 Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year? | 12m 55s | ||||||
| 9/13/26 | Antipsychotics and Weight Gain | In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know Antipsychotic-Induced Weight Gain: Prevention and Management | 14m 59s | ||||||
| 9/8/26 | EPA vs. DHA: Fish Oil and Treatment-Resistant Depression | In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms. Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 0.75 CMEs: Quick Take Vol. 84 Eicosapentaenoic Acid: Effective as Adjunctive for TRD? | 12m 41s | ||||||
| 9/3/26 | AUD Medications and Hepatic Safety | In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status | 10m 14s | ||||||
Want analysis for the episodes below?Free for Pro Submit a request, we'll have your selected episodes analyzed within an hour. Free, at no cost to you, for Pro users. | |||||||||
| 8/29/26 | GLP-1 Agonists in Serious Mental Illness: Current Evidence | In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management? | 15m 27s | ||||||
| 8/24/26 | Gabapentin, Topiramate & Baclofen in AUD | In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder | 17m 22s | ||||||
| 8/19/26 | Deprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good | In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 84 Benzodiazepine Tapering: Key Takeaways From New Guidelines | 17m 01s | ||||||
| 8/14/26 | Disulfiram Unpacked: Efficacy, Risks, and Liver Safety | In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations | 16m 11s | ||||||
| 8/9/26 | GLP-1s and Lithium: What Clinicians Need to Know | In this episode, we explore a surprising drug interaction that every lithium-prescribing clinician should know about: can semaglutide, the widely used GLP-1 receptor agonist, push lithium levels into toxic territory — and if so, why? Faculty: Paul Zarkowski, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Can GLP-1 Agonists Elevate Lithium Levels? | 11m 59s | ||||||
| 8/4/26 | Naltrexone for Alcohol Use Disorder: What You Should Know | In this episode, we explore how naltrexone — the most widely used medication for alcohol use disorder in the US — works, how to dose it safely, and why liver disease may not be the barrier you think it is. Can a medication that doesn't target abstinence still be a game-changer for your patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder Naltrexone for Alcohol Use Disorder: Dosing, Monitoring, and Liver Safety | 13m 54s | ||||||
| 7/30/26 | The OPTIMUM Trial: A Roadmap for Treatment-Resistant Depression in Late Life | In this episode, we explore the OPTIMUM trial, a landmark study examining how to treat older adults with treatment-resistant depression when antidepressants fall short. When adding a medication outperforms switching entirely — and what that means for the patient sitting across from you — the answer may reshape your clinical approach. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. Learn more about our membership here Earn 0.75 CMEs: Quick Take Vol. 83 Antidepressant Augmentation vs. Switching in Geriatric Depression: Key Findings from the OPTIMUM Trial | 16m 31s | ||||||
| 7/25/26 | Difficult-to-Treat Depression: First, Second, and Third-Line Strategies | In this episode, we explore what to do when antidepressants aren't working. How do you systematically approach a patient who isn't getting better — and when do you switch versus augment? Dr. Sagar Parikh walks through CANMAT's evidence-based framework for difficult-to-treat depression. Faculty: Sagar V. Parikh, M.D., F.R.C.P.C. Host: Richard Seeber, M.D. Learn more about our memberships here Earn 1.25 CME: Rethinking Depression Treatment: An Update of CANMAT's Guidelines Pharmacologic Management of Difficult-to-Treat Depression: First, Second, and Third Line Options | 15m 19s | ||||||
| 7/20/26 | high-dose olanzapinetreatment-resistant schizophrenia+3 | Oliver Freudenreich, M.D. | Psychopharmacology Institute | — | high-dose olanzapineclozapine+6 | — | 10m 32s | ||
| 7/15/26 | CANMAT guidelinescomplementary medicine+3 | Sagar V. Parikh, M.D., F.R.C.P.C. | St. John's wortsaffron+1 | — | CANMATdepression+6 | — | 7m 41s | ||
| 7/10/26 | xylazinetoxicology+3 | David A. Gorelick, M.D., Ph.D., D.L.F.A.P.A., F.A.S.A.M.David A. Gorelick | naloxonexylazine+1 | — | xylazinenaloxone+4 | — | 9m 20s | ||
| 7/5/26 | depression treatmentCANMAT guidelines+3 | Sagar V. Parikh, M.D. | CANMAT | — | depressiontreatment+5 | — | 18m 39s | ||
| 6/30/26 | deprescribingantipsychotics+3 | — | Psychopharmacology Institute | — | deliriumantipsychotics+3 | — | 14m 49s | ||
| 6/25/26 | long-acting injectablesschizophrenia treatment+3 | Brian Miller, M.D., Ph.D., M.P.H.Brian Miller | paliperidone palmitaterisperidone | — | paliperidonerisperidone+5 | — | 15m 02s | ||
| 6/20/26 | antipsychotic switchingclinical tips+3 | Oliver Freudenreich | Psychopharmacology Institute | — | antipsychoticsswitching+4 | — | 12m 01s | ||
| 6/15/26 | long-acting injectablesantipsychotics+3 | Brian Miller, M.D., Ph.D., M.P.H.Brian Miller | aripiprazoleolanzapine+4 | — | long-acting injectablesaripiprazole+4 | — | 11m 54s | ||
| 6/5/26 | schizophrenialong-acting injectable antipsychotics+3 | — | Psychopharmacology Institute | — | LAIsschizophrenia+5 | — | 7m 43s | ||
| 5/31/26 | Alzheimer's diseaselithium+4 | Scott Beach, M.D. | Lithium OrotateNature | — | lithiumAlzheimer's disease+5 | — | 11m 30s | ||
Showing 28 of 100
Pitch Fit is a Pro feature
See how bookable this show is for guests, which brands already advertise, the per-episode ad value, and the best-fit guest and sponsor profile. The numbers are blurred on the free plan.
How readily this show books outside guests like you.
How proven this show is for host-read sponsorships.
For Guests
ProFor Advertisers
ProUpgrade to Pro to unlock guest cadence, sponsor categories, fit scores, and per-episode ad value for this show.
Similar Audience Demographics
Podcasts that attract a similar listener profile
The Carlat Psychiatry Podcast
The Carlat Psychiatry Podcast
PsychRounds: The Psychiatry Podcast
Dr. Tanner Hewitt, Dr. Larry Wang and Dr. Bradley Miller
NEI Podcast
Neuroscience Education Institute
Psychiatry Boot Camp
Mark Mullen, MD
Psychiatry & Psychotherapy Podcast
David Puder, M.D.
Psychofarm Podcast
Psychiatry, Skepticism, and Integration.
PsychEd: Educational Psychiatry Podcast
PsychEd
Chart history for Psychopharmacology and Psychiatry Updates
Peaked at #13 in SA, currently #13 in SA.
| Market | Genre | Peak | Current | Trend |
|---|---|---|---|---|
| SA | — | #13 | #13 | — |
| CZ | — | #30 | #30 | — |
| HU | — | #41 | #41 | — |
| South Africa | — | #43 | #43 | — |
| SA | — | #47 | #47 | — |
| TH | — | #49 | #49 | — |
| VN | — | #63 | #63 | — |
| Finland | — | #73 | #73 | — |
| IL | — | #74 | #74 | — |
| IS | — | #77 | #77 | — |
| Canada | — | #83 | #83 | — |
| United States | — | #84 | #84 | — |
| Sweden | — | #84 | #84 | — |
| AR | — | #91 | #91 | — |
| TR | — | #95 | #95 | — |
| India | — | #97 | #97 | — |
| CL | — | #99 | #99 | — |
| MY | — | #111 | #111 | — |
| ID | — | #123 | #123 | — |
| HK | — | #137 | #137 | — |
Chart Positions
29 placements across 28 markets.
Chart Positions
29 placements across 28 markets.